Nadolol Uses, Dosage, Side Effects & Warnings | DrugsAtlas
Authoritative Clinical Reference
Navigation
DRUG NAME: Nadolol
Therapeutic Class: Beta-blocker
Subclass: Non-selective beta-adrenergic antagonist
Speciality: Cardiology
Subclass: Non-selective beta-adrenergic antagonist
Speciality: Cardiology
Schedule (India): Schedule H
Route(s): Oral
Formulations Available in India:
• Tablets: 40 mg, 80 mg
• Note: Limited availability in India; primarily hospital-based supply or special import
Route(s): Oral
Formulations Available in India:
• Tablets: 40 mg, 80 mg
• Note: Limited availability in India; primarily hospital-based supply or special import
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
▶ Hypertension
| Parameter | Recommendation |
|
Starting dose
|
40 mg once daily |
|
Titration
|
Increase by 40–80 mg/day at 1–2 week intervals based on blood pressure response |
|
Usual maintenance dose
|
40–80 mg once daily |
|
Maximum dose
|
320 mg once daily |
Clinical Notes:
• Long half-life (20–24 hours) permits true once-daily dosing
• Non-cardioselective — avoid in patients with reactive airway disease
• Monitor for bradycardia during titration
• Long half-life (20–24 hours) permits true once-daily dosing
• Non-cardioselective — avoid in patients with reactive airway disease
• Monitor for bradycardia during titration
▶ Angina Pectoris (chronic stable)
| Parameter | Recommendation |
|
Starting dose
|
40 mg once daily |
|
Titration
|
Increase every 3–7 days based on clinical response and heart rate |
|
Usual maintenance dose
|
80–160 mg once daily |
|
Maximum dose
|
240 mg/day |
Clinical Notes:
• Reduces myocardial oxygen demand through reduction of heart rate and contractility
• Effective for exercise-induced angina
• Avoid abrupt discontinuation — may precipitate angina or myocardial infarction
• Reduces myocardial oxygen demand through reduction of heart rate and contractility
• Effective for exercise-induced angina
• Avoid abrupt discontinuation — may precipitate angina or myocardial infarction
Secondary Indications — Adults (Off-label, if any)
▶ Portal Hypertension / Variceal Bleeding Prophylaxis — OFF-LABEL
| Parameter | Recommendation |
|
Starting dose
|
20 mg once daily |
|
Titration
|
Titrate to decrease resting heart rate by approximately 25% or to achieve heart rate of 55–60 bpm |
|
Usual maintenance dose
|
40–80 mg once daily |
|
Maximum dose
|
160 mg/day |
|
Duration
|
Long-term for primary/secondary prophylaxis |
• Specialist only — typically used in hepatology/gastroenterology settings
• Evidence basis: Established use in Indian hepatology practice; supported by international randomized studies
• Evidence basis: Established use in Indian hepatology practice; supported by international randomized studies
▶ Migraine Prophylaxis — OFF-LABEL
| Parameter | Recommendation |
|
Starting dose
|
40 mg once daily |
|
Titration
|
Increase by 40 mg every 2–4 weeks based on response and tolerability |
|
Usual maintenance dose
|
80–160 mg once daily |
|
Maximum dose
|
240 mg/day |
|
Duration
|
Minimum 2–3 months trial; continue 6–12 months if effective, then consider tapering |
Clinical Notes:
• Effective for reducing migraine frequency and severity
• Long half-life offers advantage of once-daily dosing with stable blood levels
• Allow 4–6 weeks at target dose before assessing efficacy
• Taper gradually when discontinuing
• Preferred alternative in India: Propranolol (more commonly used, better availability, NLEM-listed)
• Effective for reducing migraine frequency and severity
• Long half-life offers advantage of once-daily dosing with stable blood levels
• Allow 4–6 weeks at target dose before assessing efficacy
• Taper gradually when discontinuing
• Preferred alternative in India: Propranolol (more commonly used, better availability, NLEM-listed)
• Specialist only — under neurology guidance for refractory cases
• Evidence basis: Established in international guidelines; Indian neurology practice routinely uses beta-blockers for migraine prophylaxis
• Evidence basis: Established in international guidelines; Indian neurology practice routinely uses beta-blockers for migraine prophylaxis
▶ Thyrotoxicosis (Symptomatic Control) — OFF-LABEL
| Parameter | Recommendation |
|
Starting dose
|
40 mg once daily |
|
Titration
|
Increase every 3–7 days based on heart rate and symptom control |
|
Usual maintenance dose
|
40–160 mg once daily |
|
Maximum dose
|
160 mg/day (higher doses rarely needed) |
|
Duration
|
Until euthyroid state achieved with definitive therapy (antithyroid drugs, radioiodine, or surgery) |
Clinical Notes:
• Provides symptomatic relief of adrenergic symptoms: tachycardia, palpitations, tremor, anxiety, heat intolerance
• Does NOT inhibit peripheral T4 to T3 conversion (unlike propranolol)
• Adjust dose to maintain resting heart rate 60–80 bpm
• Long half-life allows once-daily dosing — useful for compliance
• Preferred alternative in India: Propranolol — additionally blocks peripheral conversion of T4 to T3; better availability
• Provides symptomatic relief of adrenergic symptoms: tachycardia, palpitations, tremor, anxiety, heat intolerance
• Does NOT inhibit peripheral T4 to T3 conversion (unlike propranolol)
• Adjust dose to maintain resting heart rate 60–80 bpm
• Long half-life allows once-daily dosing — useful for compliance
• Preferred alternative in India: Propranolol — additionally blocks peripheral conversion of T4 to T3; better availability
• Specialist only — under endocrinology guidance
• Evidence basis: Standard practice in hyperthyroidism management; propranolol preferred but nadolol acceptable alternative
• Evidence basis: Standard practice in hyperthyroidism management; propranolol preferred but nadolol acceptable alternative
▶ Long QT Syndrome (LQTS) / Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) — OFF-LABEL
| Parameter | Recommendation |
|
Starting dose
|
40 mg once daily |
|
Titration
|
Increase gradually based on heart rate and clinical response |
|
Usual maintenance dose
|
40–160 mg once daily |
|
Maximum dose
|
160–240 mg/day |
• Specialist only — under electrophysiology/cardiology guidance
• Evidence basis: International experience and guidelines; emerging evidence supports nadolol as preferred beta-blocker for LQTS due to long half-life and consistent beta-blockade
• Evidence basis: International experience and guidelines; emerging evidence supports nadolol as preferred beta-blocker for LQTS due to long half-life and consistent beta-blockade
PAEDIATRIC DOSING (Specialist Only)
Primary Indications (Approved / Standard in India)
Not formally approved for paediatric indications in India.
Secondary Indications — Paediatric Doses (Off-label, if any)
▶ Long QT Syndrome (LQTS) / Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) — OFF-LABEL
| Parameter | Recommendation |
|
Starting dose
|
0.5–1 mg/kg/day once daily |
|
Titration
|
Increase every 3–7 days based on heart rate and QTc response |
|
Usual maintenance dose
|
1–2 mg/kg/day once daily |
|
Maximum dose
|
4 mg/kg/day |
|
Minimum age
|
Not recommended below 3 years except under paediatric electrophysiologist guidance |
• Specialist only — requires paediatric cardiology/electrophysiology supervision
• Evidence basis: International paediatric cardiology practice; limited Indian data
• Evidence basis: International paediatric cardiology practice; limited Indian data
▶ Migraine Prophylaxis (Paediatric) — OFF-LABEL
| Parameter | Recommendation |
|
Starting dose
|
0.5–1 mg/kg/day once daily |
|
Titration
|
Increase by 0.5 mg/kg/day every 2–4 weeks based on response |
|
Usual maintenance dose
|
1–2 mg/kg/day once daily |
|
Maximum dose
|
2.5 mg/kg/day or 160 mg/day (whichever is lower) |
|
Duration
|
Minimum 2–3 months trial |
|
Minimum age
|
Not recommended below 6 years without paediatric neurology guidance |
• Specialist only — under paediatric neurology supervision
• Evidence basis: Limited paediatric data; propranolol is preferred in Indian paediatric practice due to better availability and more experience
• Preferred alternative: Propranolol
• Evidence basis: Limited paediatric data; propranolol is preferred in Indian paediatric practice due to better availability and more experience
• Preferred alternative: Propranolol
Safety Monitoring (All Paediatric Indications):
• Baseline and periodic ECG (monitor QTc interval in LQTS/CPVT)
• Maintain resting heart rate >50–55 bpm
• Target QTc <500 ms (in LQTS)
• Monitor blood pressure and symptoms of fatigue/dizziness
• Monitor growth parameters with long-term use
• Baseline and periodic ECG (monitor QTc interval in LQTS/CPVT)
• Maintain resting heart rate >50–55 bpm
• Target QTc <500 ms (in LQTS)
• Monitor blood pressure and symptoms of fatigue/dizziness
• Monitor growth parameters with long-term use
Clear statement: Use in children is off-label and restricted to specialist paediatric cardiology, electrophysiology, or neurology centres.
RENAL ADJUSTMENT
| eGFR (mL/min/1.73m²) | Recommendation |
| >80 | No dose adjustment required |
| 50–80 | Reduce dose by 50% or extend dosing interval to every 48 hours |
| 10–50 | Use 25–50% of usual dose; monitor heart rate and blood pressure closely |
| <10 | Use with extreme caution; avoid if bradycardia risk is high |
Haemodialysis: Nadolol is not efficiently dialysed; supplemental post-dialysis dosing not required.
Peritoneal dialysis: Limited data; use with caution; monitor for accumulation.
Note: Nadolol is excreted unchanged via kidneys — dose adjustment is essential in renal impairment.
HEPATIC ADJUSTMENT
| Severity | Recommendation |
| Mild impairment | No specific dose adjustment required |
| Moderate impairment | No specific dose adjustment required; monitor haemodynamic parameters |
| Severe impairment | Use with caution; consider reduced dosing frequency; monitor for excessive bradycardia or hypotension due to altered haemodynamics |
CONTRAINDICATIONS
• Sinus bradycardia (<50 bpm)
• Second or third-degree atrioventricular block (without pacemaker)
• Cardiogenic shock
• Acute decompensated heart failure
• Bronchial asthma
• Severe chronic obstructive pulmonary disease
• Known hypersensitivity to nadolol or other beta-blockers
• Sick sinus syndrome (without pacemaker)
• Severe peripheral arterial disease with critical limb ischaemia
• Untreated phaeochromocytoma
• Second or third-degree atrioventricular block (without pacemaker)
• Cardiogenic shock
• Acute decompensated heart failure
• Bronchial asthma
• Severe chronic obstructive pulmonary disease
• Known hypersensitivity to nadolol or other beta-blockers
• Sick sinus syndrome (without pacemaker)
• Severe peripheral arterial disease with critical limb ischaemia
• Untreated phaeochromocytoma
CAUTIONS
• Diabetes mellitus — may mask hypoglycaemia symptoms (tachycardia, tremor)
• Peripheral vascular disease — may exacerbate claudication symptoms
• History of severe anaphylactic reactions — may blunt response to epinephrine
• Abrupt withdrawal — may precipitate angina, myocardial infarction, or arrhythmias; always taper gradually over 1–2 weeks
• Psoriasis — may worsen skin lesions
• Depression — beta-blockers may exacerbate mood disorders
• Thyrotoxicosis — may mask clinical signs; avoid abrupt withdrawal
• Prinzmetal (variant) angina — potential for coronary vasospasm
• First-degree atrioventricular block
• Myasthenia gravis — may worsen muscle weakness
• Renal impairment — requires dose adjustment
• Peripheral vascular disease — may exacerbate claudication symptoms
• History of severe anaphylactic reactions — may blunt response to epinephrine
• Abrupt withdrawal — may precipitate angina, myocardial infarction, or arrhythmias; always taper gradually over 1–2 weeks
• Psoriasis — may worsen skin lesions
• Depression — beta-blockers may exacerbate mood disorders
• Thyrotoxicosis — may mask clinical signs; avoid abrupt withdrawal
• Prinzmetal (variant) angina — potential for coronary vasospasm
• First-degree atrioventricular block
• Myasthenia gravis — may worsen muscle weakness
• Renal impairment — requires dose adjustment
PREGNANCY
| Consideration | Recommendation |
| Overall safety | Use only if clearly needed; nadolol crosses placenta |
| Risk | Fetal bradycardia, hypoglycaemia, intrauterine growth restriction, low birth weight |
| Preferred alternatives | Labetalol, methyldopa for hypertension in pregnancy (better established safety data); propranolol for other indications |
| When it may be used | Only if benefit clearly outweighs risk and preferred alternatives are not suitable |
| Monitoring | Fetal growth (serial ultrasound), fetal heart rate; neonatal heart rate, blood pressure, and glucose monitoring for 48–72 hours post-delivery |
LACTATION
| Consideration | Recommendation |
| Compatibility | Compatible with caution |
| Drug levels in milk | Low to moderate; long half-life may lead to accumulation in infant |
| Preferred alternatives | Propranolol, metoprolol (more breastfeeding data available) |
| Infant monitoring | Heart rate, feeding, weight gain, signs of beta-blockade (lethargy, poor feeding) |
• Avoid in mothers of preterm or low birth weight infants due to potential for accumulation
• If used, monitor infant closely for first 2 weeks
• If used, monitor infant closely for first 2 weeks
ELDERLY
| Consideration | Recommendation |
| Starting dose | 20–40 mg once daily |
| Titration | Slower titration recommended (increase dose at 2-week intervals) |
| Risks | Bradycardia, hypotension, dizziness, falls, cognitive effects, depression |
| Monitoring | Renal function, heart rate, orthostatic blood pressure |
• Renal clearance is often reduced in elderly — adjust dose accordingly
• Increased sensitivity to CNS effects
• Assess fall risk before initiation
• Increased sensitivity to CNS effects
• Assess fall risk before initiation
MAJOR DRUG INTERACTIONS
| Interacting Drug | Effect / Mechanism | Recommendation |
| Verapamil, Diltiazem | Additive negative chronotropic and dromotropic effects; increased risk of bradycardia, AV block, heart failure |
Avoid combination or use with extreme caution under specialist supervision
|
| Clonidine | Risk of severe rebound hypertension if clonidine stopped without first tapering beta-blocker |
Discontinue nadolol several days before stopping clonidine
|
| Amiodarone | Additive bradycardia and conduction abnormalities |
Use with caution; monitor ECG and heart rate closely
|
| Class I antiarrhythmics (quinidine, disopyramide, flecainide) | Additive negative inotropic effects; risk of severe bradycardia and heart failure |
Avoid or use with extreme caution
|
| Insulin and sulfonylureas | Beta-blockade masks hypoglycaemia symptoms (tachycardia, tremor); may prolong hypoglycaemia |
Monitor blood glucose closely; educate patient on hypoglycaemia signs
|
| MAOIs | Risk of severe hypertension |
Avoid combination
|
| Fingolimod | Additive bradycardia risk |
Avoid initiation of fingolimod in patients on nadolol
|
MODERATE DRUG INTERACTIONS
| Interacting Drug | Effect / Mechanism | Recommendation |
| NSAIDs | May blunt antihypertensive effect via prostaglandin inhibition and sodium retention | Monitor blood pressure |
| Digoxin | Additive bradycardia risk | Monitor heart rate; consider dose adjustment |
| Rifampicin | May reduce beta-blocker efficacy via hepatic enzyme induction | Monitor clinical response; may need dose adjustment |
| Tricyclic antidepressants | Additive bradycardia and orthostatic hypotension | Monitor heart rate and blood pressure |
| SSRIs (fluoxetine, paroxetine) | CYP2D6 inhibition may increase nadolol levels; potential additive bradycardia | Monitor heart rate |
| Alcohol | Additive hypotensive effects | Advise moderation |
| Anaesthetic agents | Enhanced hypotensive effect | Inform anaesthetist of beta-blocker use; do not discontinue abruptly before surgery |
| Antithyroid drugs | May require nadolol dose reduction as patient becomes euthyroid | Monitor heart rate and adjust dose |
| Ergot alkaloids | Additive vasoconstriction | Monitor for peripheral ischaemia |
| Antipsychotics | Additive hypotension | Monitor blood pressure |
COMMON ADVERSE EFFECTS
• Fatigue
• Dizziness
• Bradycardia
• Cold extremities
• Sleep disturbances (insomnia, vivid dreams, nightmares)
• Gastrointestinal upset (nausea, diarrhoea, constipation)
• Exercise intolerance
• Erectile dysfunction
• Weight gain
• Dry mouth
• Dizziness
• Bradycardia
• Cold extremities
• Sleep disturbances (insomnia, vivid dreams, nightmares)
• Gastrointestinal upset (nausea, diarrhoea, constipation)
• Exercise intolerance
• Erectile dysfunction
• Weight gain
• Dry mouth
SERIOUS ADVERSE EFFECTS
| Adverse Effect | Clinical Note |
| Symptomatic bradycardia or AV block | May require dose reduction or discontinuation; atropine or temporary pacing may be needed in severe cases |
| Bronchospasm / Exacerbation of asthma or COPD | Discontinue immediately; non-selective beta-blockers contraindicated in reactive airway disease |
| Heart failure decompensation | Monitor closely in patients with borderline cardiac function; discontinue if new or worsening heart failure |
| Severe hypotension | Especially with concurrent antihypertensives or in volume-depleted patients |
| Masked hypoglycaemia | Particularly dangerous in insulin-dependent diabetics; educate patients |
| Withdrawal-induced angina or myocardial infarction | Always taper gradually over 1–2 weeks; never stop abruptly |
| Severe depression or psychosis | Rare; discontinue if significant psychiatric symptoms develop |
| Raynaud’s phenomenon / Peripheral ischaemia | May require discontinuation |
MONITORING REQUIREMENTS
| Phase | Parameters |
|
Baseline
|
Heart rate, blood pressure, ECG, renal function (serum creatinine, eGFR), blood glucose (in diabetics), thyroid function (if indicated) |
|
After initiation/dose change
|
Heart rate and blood pressure after 1–2 weeks; symptoms of fatigue, dizziness, depression |
|
Long-term
|
Heart rate, blood pressure, renal function every 3–6 months in stable patients; periodic assessment of mood and exercise tolerance |
Indication-specific monitoring:
• Portal hypertension: Target heart rate 55–60 bpm or 25% reduction from baseline
• LQTS/CPVT: Periodic ECG; ensure consistent beta-blockade
• Migraine: Headache diary; assess efficacy after 2–3 months
• Thyrotoxicosis: Heart rate, tremor, thyroid function tests; adjust dose as patient becomes euthyroid
• Portal hypertension: Target heart rate 55–60 bpm or 25% reduction from baseline
• LQTS/CPVT: Periodic ECG; ensure consistent beta-blockade
• Migraine: Headache diary; assess efficacy after 2–3 months
• Thyrotoxicosis: Heart rate, tremor, thyroid function tests; adjust dose as patient becomes euthyroid
BRANDS AVAILABLE IN INDIA
• Corgard (limited availability — may require import)
• Nadolol tablets (institutional/hospital supply)
• Nadolol tablets (institutional/hospital supply)
Note: Nadolol is not routinely available in retail pharmacies in India. Availability should be confirmed through hospital/institutional procurement or special import channels. Propranolol is the more readily available non-selective beta-blocker alternative.
PRICE RANGE (INR)
• Approximately ₹8–₹15 per 40 mg tablet (when available)
• Approximately ₹12–₹20 per 80 mg tablet (when available)
• Prices variable due to import/special procurement requirements
• Not included in NLEM
• Not under NPPA price control
• Government supply: Generally not available through public health system
• Approximately ₹12–₹20 per 80 mg tablet (when available)
• Prices variable due to import/special procurement requirements
• Not included in NLEM
• Not under NPPA price control
• Government supply: Generally not available through public health system
CLINICAL PEARLS
• Nadolol has one of the longest half-lives among beta-blockers (20–24 hours) — allows true once-daily dosing with excellent patient compliance and stable blood levels throughout 24 hours
• Preferred choice for portal hypertension prophylaxis in cirrhosis when available due to long half-life and consistent beta-blockade; propranolol is the practical alternative in India
• For migraine prophylaxis, propranolol is preferred in India due to wider availability and NLEM listing; nadolol is a suitable alternative when once-daily dosing improves compliance or propranolol is not tolerated
• In thyrotoxicosis, propranolol is preferred as it additionally inhibits peripheral T4 to T3 conversion; nadolol is useful when once-daily dosing is advantageous or propranolol causes intolerable side effects
• Non-selective nature makes it unsuitable for patients with asthma or COPD — cardioselective alternatives (bisoprolol, metoprolol) are preferred in such patients
• Dose adjustment is essential in renal impairment as nadolol is excreted unchanged by kidneys — one of the few beta-blockers requiring significant renal dose modification
• Abrupt discontinuation can precipitate serious cardiovascular events (angina, myocardial infarction, arrhythmias, rebound hypertension) — always taper gradually over 1–2 weeks
• Limited availability in India may necessitate alternative beta-blockers for most indications; confirm availability before prescribing
TAGS
nadolol; beta-blocker; non-selective; antihypertensive; angina; portal hypertension; variceal prophylaxis; migraine prophylaxis; thyrotoxicosis; hyperthyroidism; long-acting; renal-dose-adjustment; LQTS; CPVT; Schedule H
VERSION
RxIndia v1.1 — 19 Feb 2026
REFERENCES
• CDSCO
• Indian Pharmacopoeia (IP)
• National Formulary of India (NFI)
• API Textbook of Medicine
• AIIMS Treatment Guidelines (Gastroenterology, Neurology, Endocrinology)
• ICMR Guidelines on Cirrhosis Management
• Goodman & Gilman’s The Pharmacological Basis of Therapeutics
• Harrison’s Principles of Internal Medicine
• Indian Association of Clinical Medicine protocols
• International RCTs and meta-analyses (for off-label arrhythmia, migraine, and portal hypertension use)
• Indian hepatology and neurology specialist practice protocols
• Indian Pharmacopoeia (IP)
• National Formulary of India (NFI)
• API Textbook of Medicine
• AIIMS Treatment Guidelines (Gastroenterology, Neurology, Endocrinology)
• ICMR Guidelines on Cirrhosis Management
• Goodman & Gilman’s The Pharmacological Basis of Therapeutics
• Harrison’s Principles of Internal Medicine
• Indian Association of Clinical Medicine protocols
• International RCTs and meta-analyses (for off-label arrhythmia, migraine, and portal hypertension use)
• Indian hepatology and neurology specialist practice protocols
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.